Clearance of circulating Epstein-Barr virus DNA in children with acute malaria after antimalaria treatment

J Infect Dis. 2006 Apr 1;193(7):971-7. doi: 10.1086/500839. Epub 2006 Mar 1.

Abstract

Children living in malaria-endemic regions have a high incidence of Burkitt lymphoma (BL), the etiology of which involves Plasmodium falciparum malaria and Epstein-Barr virus (EBV) infections. In the present study, we compared EBV DNA loads in plasma and saliva samples from Ugandan children with acute malaria (M+) at the time of diagnosis and 14 days after antimalaria treatment, children without malaria (M-), and children with BL. EBV DNA was detected, by real-time polymerase chain reaction, in 31% of the plasma and in 79% of the saliva samples from children in the M+ group. Antimalaria treatment led to clearance of plasma viral load in 85% of the cases but did not affect the levels in saliva. There was a significant difference in plasma EBV loads across the groups. The lowest levels were detected in samples from the M- group, increased levels were detected in samples from the M+ group, and levels reached the highest values in samples from children with BL. The same trend was evident in the frequency and levels of anti-BZLF1 antibodies, which is indicative of viral reactivation. In the M+ group, the positive plasma samples clustered around 7-9 years of age, the peak incidence of BL. The clearance of circulating EBV after antimalaria treatment suggests a direct relationship between active malaria infection and viral reactivation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Aging
  • Antibodies, Viral / blood
  • Antimalarials / therapeutic use*
  • Burkitt Lymphoma / virology
  • Child
  • Child, Preschool
  • DNA, Viral / analysis*
  • DNA-Binding Proteins / immunology
  • Epstein-Barr Virus Infections / virology*
  • Herpesvirus 4, Human / drug effects
  • Herpesvirus 4, Human / genetics
  • Herpesvirus 4, Human / isolation & purification
  • Herpesvirus 4, Human / physiology*
  • Humans
  • Malaria, Falciparum / complications
  • Malaria, Falciparum / drug therapy*
  • Malaria, Falciparum / virology
  • Polymerase Chain Reaction
  • Saliva / virology
  • Trans-Activators / immunology
  • Uganda
  • Viral Load*
  • Viral Proteins / immunology

Substances

  • Antibodies, Viral
  • Antimalarials
  • BZLF1 protein, Herpesvirus 4, Human
  • DNA, Viral
  • DNA-Binding Proteins
  • Trans-Activators
  • Viral Proteins